IGFBP1 and Insulin resistance: Chronically increased levels of insulin decrease circulating IGFBP-1, which correlates closely with whole-body and hepatic insulin resistance as well as with metabolic dysfunction-associated steatotic liver disease (MASLD) [14,18].